Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 33515500

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Respir Med
Publication date
2021 Jun
First author
de Gooijer CJ

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Respir Med. 2021 Jun;9(6):547-549. doi: 10.1016/S2213-2600(20)30516-6.
    note
    Source null
    related pmid
    33515502
    relationship
    Comment in

Authors and identifiers

  1. name
    de Gooijer CJ
    type
    Author
  2. name
    van der Noort V
    type
    Author
  3. name
    Stigt JA
    type
    Author
  4. name
    Baas P
    type
    Author
  5. name
    Biesma B
    type
    Author
  6. name
    Cornelissen R
    type
    Author
  7. name
    van Walree N
    type
    Author
  8. name
    van Heemst RC
    type
    Author
  9. name
    Soud MY
    type
    Author
  10. name
    Groen HJM
    type
    Author
  11. name
    den Brekel AJS
    type
    Author
  12. name
    Buikhuisen WA
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    de Gooijer CJ
    type
    Author
  2. name
    van der Noort V
    type
    Author
  3. name
    Stigt JA
    type
    Author
  4. name
    Baas P
    type
    Author
  5. name
    Biesma B
    type
    Author
  6. name
    Cornelissen R
    type
    Author
  7. name
    van Walree N
    type
    Author
  8. name
    van Heemst RC
    type
    Author
  9. name
    Soud MY
    type
    Author
  10. name
    Groen HJM
    type
    Author
  11. name
    den Brekel AJS
    type
    Author
  12. name
    Buikhuisen WA
    type
    Author
bibliography ids
  1. nci-bib-73964565e309cf50b8397bcb
book metadata
content sha256
c4c0c68584471dad741a68b768b3cbcdc3c53a9c392de931b5036e9e33ebe64a
document type
citation
dois
  1. 10.1016/S2213-2600(20)30362-3
electronic publication date
display
2021 Jan 27
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:33515500
immutable id
pubmed:33515500@c4c0c68584471dad741a68b768b3cbcdc3c53a9c392de931b5036e9e33ebe64a
journal
abbreviation
Lancet Respir Med
issn electronic
2213-2619
issn print
2213-2600
issue
6
name
The Lancet. Respiratory medicine
nlm unique id
101605555
pages
585-592
volume
9
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Respir Med. 2021 Jun;9(6):547-549. doi: 10.1016/S2213-2600(20)30516-6.
    note
    Source null
    related pmid
    33515502
    relationship
    Comment in
outcomes validated
false
pmid
33515500
provenance
batch id
79f1021053e858d13ff3
provider
NCBI PubMed ESummary
record sha256
0d8b63d5756296faee02e92725fcf8fa7971b16b1dfdb62ac7ed7e20f0a1f06f
response sha256
671d3d2962f73c698a1cb338d73222e2cc6cfdf61569f91b42612d5b59822e05
retrieved at
2026-09-09T23:47:59.098265+00:00
publication date
display
2021 Jun
precision
month
year
2021
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/33515500/
title
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.

Preserved source evidence · Not medical advice